Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Tolerability in Patients with Multiple Myeloma Treated with Daratumumab: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials

Thura Win Htut, MBBS, MRCP, Myint Aung Win, MDMBBS, Sriman Swarup, MDMBBS, Anita Sultan, MD, Nimesh Adhikari, MD, Ei Moe Phyu, MD, Akshar Dash, Myat Min Han, MD, Yin Mon Myat, MD, Sanjay Awasthi, MD, Lukman Tijani, MD, Nicholas D'Cunha, MD, Donald P. Quick, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 1873.

https://doi.org/10.1182/blood-2019-123164

Published: 2019

Journal Articles

Efficacy of Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Post-Lenalidomide: Results from a Systematic Literature Review and Indirect Treatment Comparison

Katja C. Weisel, MD, Sujith Dhanasiri, Aline Gauthier, Amie Padhiar, Eva Casal, Paul G. Richardson, MD

Blood (2019) 134 (Supplement_1): 2201.

https://doi.org/10.1182/blood-2019-123639

Published: 2019

Journal Articles

Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled Trials

Thura Win Htut, MBBS, MRCP, Kyaw Zin Thein, MDMBBS, Anita Sultan, MD, Sriman Swarup, MDMBBS, Myint Aung Win, MDMBBS, Ei Moe Phyu, MD, Sanjay Awasthi, MD, Akshar Dash, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Lukman Tijani, MD, Nicholas D'Cunha, MD, Donald P. Quick, MD

Blood (2019) 134 (Supplement_1): 3485.

https://doi.org/10.1182/blood-2019-123145

Published: 2019

Journal Articles

Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials

Arafat Ali Farooqui, MD, Humaira Sarfraz, MD, Zunairah Shah, MBBS, Muhammad Saad Farooqi, MD, Maimoona Khan, MBBS, Aqsa Ashraf, MD, Ahmad Anjum, MD, Talha Bin Farooq, MD, Tanveer Shaukat, MD, Ali Younas Khan, MD, Madeeha Shafqat, Muhammad Junaid Tariq, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5546.

https://doi.org/10.1182/blood-2019-121999

Published: 2019

Journal Articles

Incidence of Second Primary Malignancies and Peripheral Sensory Neuropathy in Patients with Multiple Myeloma Receiving Daratumumab Containing Regimen

Thura Win Htut, MBBS, MRCP, Donald P. Quick, MD, Myint Aung Win, MDMBBS, Sriman Swarup, MDMBBS, Anita Sultan, MD, Somedeb Ball, MD, Ei Moe Phyu, MD, Nyein Htway Yu, MBBS, MD, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Nicholas D'Cunha, MD, Sanjay Awasthi, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5550.

https://doi.org/10.1182/blood-2019-123156

Published: 2019

Journal Articles

Prevention and Management of Daratumumab Mediated Infusion Related Hypersensitivity Reactions Pre-and Post-Implementation of Rapid Infusion Protocol

My L Nguyen, PharmD, Catherine Burdalski, PharmD, BCOP, Syed Abbas Ali, MD, Lindsay Kohler, BS, PharmD Candidate, Steven Gilmore, PharmD, BCOP

Blood (2019) 134 (Supplement_1): 5811.

https://doi.org/10.1182/blood-2019-125391

Published: 2019

Journal Articles

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor

Katja C. Weisel, MD, Pieter Sonneveld, Maria-Victoria Mateos, Vania T.M. Hungria, MD PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Jane Estell, FRACP, Wolney G Barreto, Paolo Corradini, Chang-Ki Min, MD PhD, Eva Medvedova, MD, Maria Krevvata, PhD, Sonali Trivedi, Xiang Qin, Huiling Pei, PhD, Jon Ukropec, PhD, Rachel Kobos, MD, Ming Qi, MD PhD, Ajay K Nooka, MDMPH

Blood (2019) 134 (Supplement_1): 3192.

https://doi.org/10.1182/blood-2019-123527

Published: 2019

Journal Articles

Updated Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Infection and Pneumonia in Patients with Multiple Myeloma Treated with Daratumumab

Thura Win Htut, MBBS, MRCP, Aung M Tun, MD, Anita Sultan, MD, Myint Aung Win, MDMBBS, Sriman Swarup, MDMBBS, Ei Moe Phyu, MD, Pwint Phyu Hlaing, MD, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Donald P. Quick, MD, Nicholas D'Cunha, MD, Lukman Tijani, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 4771.

https://doi.org/10.1182/blood-2019-123169

Published: 2019

Journal Articles

Real World Data on the Efficacy and Safety of Daratumumab in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Hematology Centers

Blood (2018) 132 (Supplement 1): 3257.

https://doi.org/10.1182/blood-2018-99-115039

Published: 2018

Journal Articles

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor

Maria-Victoria Mateos, MD PhD, Pieter Sonneveld, MD PhD, Vania T. M. Hungria, MD PhD, Ajay K Nooka, MD MPH, Jane Estell, FRACP, Wolney G Barreto, Paolo Corradini, MD, Chang-Ki Min, MD PhD, Eva Medvedova, MD, Katja Weisel, MD, Christopher Chiu, PhD, Jordan M. Schecter, Himal Amin, Xiang Qin, Ming Qi, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2018) 132 (Supplement 1): 3270.

https://doi.org/10.1182/blood-2018-99-112554

Published: 2018

Journal Articles

Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor

Hervé Avet-Loiseau, MD PhD, Jesus F San-Miguel, MD PhD, Tineke Casneuf, PhD, Shinsuke Iida, MD PhD, Sagar Lonial, MD, Saad Z. Usmani, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Philippe Moreau, Torben Plesner, MD DSc, Katja Weisel, MD, Jon Ukropec, PhD, Linda Okonkwo, Sonali Trivedi, Christopher Joseph Velas, BS, Xiang Qin, Ming Qi, MD PhD, Christopher Chiu, PhD, Nizar Bahlis, MD

Blood (2018) 132 (Supplement 1): 3272.

https://doi.org/10.1182/blood-2018-99-113177

Published: 2018

Journal Articles

The Relationship between Minimal Residual Disease and Patient Reported Outcomes in Relapsed/Refractory Multiple Myeloma

Hervé Avet-Loiseau, MD PhD, Jianming He, PhD, Katharine S. Gries, PhD PharmD, Huiling Pei, PhD, Sourish Saha, Christopher Chiu, PhD, Sarah Cote, Annette Lam

Blood (2018) 132 (Supplement 1): 3273.

https://doi.org/10.1182/blood-2018-99-113571

Published: 2018

Journal Articles

Efficacy of Once-Weekly Bortezomib with Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma

Natalia Gut, PharmD, RPh, Filiz Yucebay, PharmD, BCPS, BCOP, Jessica Dempsey, PharmD, Junan Li, PhD MS, Don M. Benson, Jr., MD PhD

Blood (2018) 132 (Supplement 1): 1958.

https://doi.org/10.1182/blood-2018-99-111908

Published: 2018

Journal Articles

Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies

Kadriye Nehir Cosgun, PhD, Gauri Deb, MS, PhD, Xin Yang, MD, Gang Xiao, PhD, Teresa Sadras, PhD, Franziska Auer, PhD, Jaewoong Lee, PhD, Anthony Abarientos, BSc, Maurizio Mangolini, PhD, Ali Aghajanirefah, PhD, Huimin Geng, PhD, Hassan Jumaa, PhD, Andrew G. Polson, PhD, Hans Clevers, MD PhD, Markus Muschen, MD

Blood (2018) 132 (Supplement 1): 547.

https://doi.org/10.1182/blood-2018-99-116956

Published: 2018

Journal Articles

Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies

Blood (2018) 132 (Supplement 1): 3288.

https://doi.org/10.1182/blood-2018-99-112669

Published: 2018

Journal Articles

Treatment Efficacy in Relapsed/Refractory Multiple Myeloma: Outcomes Based on Racial Disparity

Hiba Jabbour, MD, Aula Rita Ramo, MD, Vijayalakshmi Donthireddy, MD

Blood (2018) 132 (Supplement 1): 5665.

https://doi.org/10.1182/blood-2018-99-119181

Published: 2018

Journal Articles

Cost-Effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Castor Trial

Eric M Maiese, Christopher N Graham, Emma Hawe, Jean-Gabriel Le Moine, Ivo Abraham, PhD RN, Mekre Senbetta

Blood (2017) 130 (Supplement 1): 3400.

https://doi.org/10.1182/blood.V130.Suppl_1.3400.3400

Published: 2017

Journal Articles

Single Agent Daratumumab in Advanced Multiple Myeloma: Specific Healthcare Program in the Czech Republic

Jiri Minarik, MD PhD, Ludek Pour, MD PhD, Vladimir Maisnar, Prof, MD PhD, Ivan Spicka, MDPhD, Alexandra Jungova, MD, Hana Plonkova, Lucie Brozova, MSc, Petra Krhovska, Tomas Pika, Jaroslav Bacovsky, Sabina Sevcikova, RNDr, PhD, Jakub Radocha, MD PhD, Vlastimil Scudla, Prof, MD CSc, Roman Hájek, MD

Blood (2017) 130 (Supplement 1): 5414.

https://doi.org/10.1182/blood.V130.Suppl_1.5414.5414

Published: 2017

Journal Articles

Comparison of Overall Survival Associated with Lenalidomide+Dexamethasone and Bortezomib+Dexamethasone Among Relapsed/Refractory Multiple Myeloma Patients: A Matched Analysis of Real World and Clinical Trial Populations

Ajay Nooka, MDMPH, Peter M. Voorhees, MD, Shaji K Kumar, MD, Maneesha Mehra, Annette Lam, Mary Slavcev, Ravi Potluri, Anandaroop Dasgupta

Blood (2017) 130 (Supplement 1): 3094.

https://doi.org/10.1182/blood.V130.Suppl_1.3094.3094

Published: 2017

Journal Articles

Daratumumab, Bortezomib, and Dexamethasone (DVd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Castor

Andrew Spencer, MD, Vania T M Hungria, MD PhD, Maria-Victoria Mateos, MD, Ajay Nooka, MDMPH, Jane Estell, Wolney G Barreto, Paolo Corradini, MD, Chang-Ki Min, MD, Eva Medvedova, MD, Piruntha Thiyagarajah, William Deraedt, Christopher Chiu, Jordan Schecter, Katja C. Weisel

Blood (2017) 130 (Supplement 1): 3145.

https://doi.org/10.1182/blood.V130.Suppl_1.3145.3145

Published: 2017

NARROW

Tolerability in Patients with Multiple Myeloma Treated with Daratumumab: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials

Efficacy of Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Post-Lenalidomide: Results from a Systematic Literature Review and Indirect Treatment Comparison

Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled Trials

Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials

Incidence of Second Primary Malignancies and Peripheral Sensory Neuropathy in Patients with Multiple Myeloma Receiving Daratumumab Containing Regimen

Prevention and Management of Daratumumab Mediated Infusion Related Hypersensitivity Reactions Pre-and Post-Implementation of Rapid Infusion Protocol

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor

Updated Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Infection and Pneumonia in Patients with Multiple Myeloma Treated with Daratumumab

Real World Data on the Efficacy and Safety of Daratumumab in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Hematology Centers

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor

Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor

The Relationship between Minimal Residual Disease and Patient Reported Outcomes in Relapsed/Refractory Multiple Myeloma

Efficacy of Once-Weekly Bortezomib with Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma

Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies

Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies

Treatment Efficacy in Relapsed/Refractory Multiple Myeloma: Outcomes Based on Racial Disparity

Cost-Effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Castor Trial

Single Agent Daratumumab in Advanced Multiple Myeloma: Specific Healthcare Program in the Czech Republic

Comparison of Overall Survival Associated with Lenalidomide+Dexamethasone and Bortezomib+Dexamethasone Among Relapsed/Refractory Multiple Myeloma Patients: A Matched Analysis of Real World and Clinical Trial Populations

Daratumumab, Bortezomib, and Dexamethasone (DVd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Castor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only